Characterization of potent ligands at human recombinant adenosine receptors

Drug Development Research

Volumn 45, Issue 3-4, 1998, Pages 176-181

  Cristalli, Gloria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; LIGAND; NUCLEOSIDE; PURINE DERIVATIVE; RADIOLIGAND;

ANIMAL CELL; BINDING AFFINITY; CHO CELL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; LIGAND BINDING; NONHUMAN; RADIOASSAY; RECEPTOR INTRINSIC ACTIVITY; STRUCTURE ACTIVITY RELATION;

EID: 0032461854     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199811/12)45:3/4<176::AID-DDR14>3.0.CO;2-G     Document Type: Conference Paper

References (31)

1. 3 fibroblasts. Biochem Pharmacol 47:801-814.
2. Camaioni E, Di Francesco E, Vittori S, Volpini R, Cristalli G. 1997. Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-l-propyn-lyI)NECA. Bioorg Med Chem 5:2267-2275.
3. Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KM, Cristalli G. 1998. New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 6:523-533.
4. 2 adenosine receptors. J Med Chem 35:2363-2368.
5. Cristalli G, Volpini R, Vittori S, Camaioni E, Monopoli A, Conti A, Dionisolli S, Zocchi C, Ongini E. 1994. 2-Alkynyl derivatives of adenosine-5′-N-ethyluronamide: selective A£ adenosine receptor agonists with potent inhibitory activity on platelet aggregation. J Med Chem 37:1720-1726.
6. Cristalli G, Camaioni E, Vittori S, Volpini R, Borea PA, Conti A, Dionisotti S, Ongini E, Monopoli A. 1995a. 2-Aralkynyl and 2heteroalkynyl derivatives of adenosine-5′-N-ethyIuronamide as selective A£A adenosine receptor agonists. J Med Chem 38:1462-1472.
7. Cristalli G, Volpini R, Vittori S, Camaioni E. 1995b. Selective A2 adenosine receptor agonists with potent inhibitor)1 activity on platelet aggregation. In: Belardinelli L, Pelleg A, editors. Adenosine and adenine nucleotides: from molecular biology to integralive physiology. Boston: Kluwer Academic Publishers, p 140-148.
8. Cristalli G, Camaioni E, Di Francesco E, Eleuteri A, Vittori S, Volpini R. 1997. Potent and selective ligands for adenosine binding sites. Nucleosides Nucleotides 16:1379-1388.
9. de Zwart M, Link R, von Frijtag Drabbe Kunzel JK, Cristalli G, Jacobson KA, Townsend-Nicholson A, Ijzerman AR 199S. A functional screening of adenosine analogues at the adenosine A£B receptor: a search for potent agonists. Nucleosides Nucleotides 17:969-985.
10. Ferkany JW, Valentine HL, Stone GA, Williams M. 19S6. Adenosine AI receptors in mammalian brain: species differences in their interactions with agonists and antagonists. Drug Dev Res 9:85-93.
11. Feoklislov I, Polosa R, Holgate ST, Biaggioni I. 1998. Adenosine A?B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sei 19:148-153. -
12. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden K, Jacobson KA, LeffP, Williams M. 1994. Nomenclature and classification of purinoccptors. Physio! Rev 46:143-156.
13. Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M. 1997. Toward a revised nomenclature for PI and P£ receptors. Trends Pharmacol Sei 18:79-82.
14. Jacobson KA, Kirn HO, Siddiqi SM, Olah ME, Stiles GL, von Lubitz DKJE. 1995. Aa-adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Fut 20:689-699.
15. Jiang J, van Rhee A, Chang L, Patchomik A, Ji X-D, Evans P, Melman N, Jacobson KA. 1997. Structure-activity relationships of 4-(phenyIethynyl)-6-phenyl-l,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J Med Chem 40:2596-2608.
16. Ji X-D, von Lubitz DKJE, Olah ME, Stiles GL, Jacobson KA. 1994. Species differences in ligand affinity at central As-adenosine receptors. Drug Dev Res 33:51-59.
17. Klotz K-N, Vogt H, Tawfik-Schlieper H. 1991. Comparison of AI adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. Naunyn Schmiedebergs Arch Pharmacol 343:196-201.
18. Klotz KN, Hessling J, Hegler J, Owman C, Kuli B, Fredholm BB, Lohse MJ. 1998. Comparative pharmacology of human adenosine receptor subtypes: characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1-9.
19. Lohse MJ, Klotz KN, Lindenborn FJ, Reddington M, Schwabe U, Olsson RA. 1987. 8-Cyclopentyl-l,3-dipropyIxanthine (DPCPX) a selective high affinity antagonist radioligand for AI adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 336:204-210.
20. Lohse MJ, Klotz KN, Schwabe U, Cristalli G, Vïttori S, Grifantini M. 1988. 2-Chloro-A'6-cyclppentyladenosine: a highly selective agonist at AI adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 337:687-689.
21. Monopoli A, Conti A, Zocchi C, Casati C, Volpini R, Cristalli G, Ongini E. 1994a. Pharmacology of the new selective Ai\ adenosine re-ceptor agonist 2-hexynyl-5′-N-ethyl-carboxamidoadenosine. Arzneim Forsch 44:1296-1304:
22. Monopoli A, Conti A, Dionisotti S, Casati C, Camaioni E, Cristalli G, Ongini E. 1994b. Pharmacology of the highly selective AI adenosine receptor agonist 2-chIoro-A76-cyclopentyIadenosine. Arzneimittel Forschung 44 (II):1305-1312.
23. Müller CE, Scior T. 1993. Adenosine receptors and their modulators. Pharni Acta Helv 68:77-111.
24. Müller CE, Stein B. 1996. Adenosine receptor antagonists: structures and potential therapeutic applications. Current Pharmaceutical Design 2:501-530.
25. Olah ME, Stiles GL. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol To.xicol 35:581-606.
26. Pierce KD, Furlong TJ, Selbie LA, Shine J. 1992. Molecular cloning and expression of an adenosine-Aou receptor from human brain. Biochem Biophys Res Commun 187:86-93.
27. Poulsen S-A, Quinn RJ. 1998. Adeno'sine receptors: new opportunities for future drugs. Bioorg Sled Chem 6:619-641.
28. Richardson PJ, Käse H, Jenner PG. 1997. Adenosine A\ receptor antagonists as new agents for the treatment of Parkinsons disease. Trends Phannacol Sei 18:338-344.
29. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. 1993. Molecular cloning and characterization of the human AS adenosine receptor. Proc Natl Acad Sei USA 90:10365-10369.
30. Stone GA, Jarvis MF, Sills MA, Weeks B, Snowhill EW, Williams M. 1988. Species differences in high-affinity adenosine AI binding sites in striatal membranes from mammalian brain. Drug Dev Res 15:31-46.
31. Vblpini R, Camaioni E, Costanzi S, Vittori S, Klotz KN, Cristalli G. 1999. Adenosine receptor agonists: the influence of combined substitutions on receptor affinity. Nucleosides Nucleotides (in press).